Edimer Pharmaceuticals raises $18m series B financing led by New Enterprise Associates and including new investor Sanofi-Genzyme BioVentures.
Edimer Pharmaceuticals, a US-based biotechnology company focused on developing a therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), announced on 30 July that it had secured $18m in series B financing led by New Enterprise Associates (NEA), with additional new investor Sanofi-Genzyme BioVentures, the $100m corporate venture capital fund of France-based pharmaceutical company Sanofi and its US-based subsidiary Genzyme. Previous investors Third Rock Ventures and VI Partners also participated.
Edimer will use the proceeds to advance the…